Identification of drug-target interactions via multiple kernel-based triple collaborative matrix factorization

scRNMF: An imputation method for single-cell RNA-seq data by robust and non-negative matrix factorization

Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful tool in genomics research, enabling the analysis of gene expression at the individual cell level. However, scRNA-seq data often suffer from a high rate of dropouts, where certain genes fail to be detected in specific cells due to technical limitations. This missing data can introduce biases and hinder downstream analysis. To overcome this challenge, the development of effective imputation methods has become crucial in the field of scRNA-seq data analysis. Here, we propose an imputation method based on robust and non-negative matrix factorization (scRNMF). Instead of other matrix factorization algorithms, scRNMF integrates two loss functions: L2 loss and C-loss. The L2 loss function is highly sensitive to outliers, which can introduce substantial errors. We utilize the C-loss function when dealing with zero values in the raw data. The primary advantage of the C-loss function is that it imposes a smaller punishment for larger errors, which results in more robust factorization when handling outliers. Various datasets of different sizes and zero rates are used to evaluate the performance of scRNMF against other state-of-the-art methods. Our method demonstrates its power and stability as a tool for imputation of scRNA-seq data.

CKG-IMC: An inductive matrix completion method enhanced by CKG and GNN for Alzheimer's disease compound-protein interactions prediction

Alzheimer's disease (AD) is one of the most prevalent chronic neurodegenerative disorders globally, with a rapidly growing population of AD patients and currently no effective therapeutic interventions available. Consequently, the development of therapeutic anti-AD drugs and the identification of AD targets represent one of the most urgent tasks. In this study, in addition to considering known drugs and targets, we explore compound-protein interactions (CPIs) between compounds and proteins relevant to AD. We propose a deep learning model called CKG-IMC to predict Alzheimer's disease compound-protein interaction relationships. CKG-IMC comprises three modules: a collaborative knowledge graph (CKG), a principal neighborhood aggregation graph neural network (PNA), and an inductive matrix completion (IMC). The collaborative knowledge graph is used to learn semantic associations between entities, PNA is employed to extract structural features of the relationship network, and IMC is utilized for CPIs prediction. Compared with a total of 16 baseline models based on similarities, knowledge graphs, and graph neural networks, our model achieves state-of-the-art performance in experiments of 10-fold cross-validation and independent test. Furthermore, we use CKG-IMC to predict compounds interacting with two confirmed AD targets, 42-amino-acid β-amyloid (Aβ42) protein and microtubule-associated protein tau (tau protein), as well as proteins interacting with five FDA-approved anti-AD drugs. The results indicate that the majority of predictions are supported by literature, and molecular docking experiments demonstrate a strong affinity between the predicted compounds and targets.

Drug-target interaction predictions with multi-view similarity network fusion strategy and deep interactive attention mechanism

MOTIVATION

Accurately identifying the drug-target interactions (DTIs) is one of the crucial steps in the drug discovery and drug repositioning process. Currently, many computational-based models have already been proposed for DTI prediction and achieved some significant improvement. However, these approaches pay little attention to fuse the multi-view similarity networks related to drugs and targets in an appropriate way. Besides, how to fully incorporate the known interaction relationships to accurately represent drugs and targets is not well investigated. Therefore, there is still a need to improve the accuracy of DTI prediction models.

RESULTS

In this study, we propose a novel approach that employs Multi-view similarity network fusion strategy and deep Interactive attention mechanism to predict Drug-Target Interactions (MIDTI). First, MIDTI constructs multi-view similarity networks of drugs and targets with their diverse information and integrates these similarity networks effectively in an unsupervised manner. Then, MIDTI obtains the embeddings of drugs and targets from multi-type networks simultaneously. After that, MIDTI adopts the deep interactive attention mechanism to further learn their discriminative embeddings comprehensively with the known DTI relationships. Finally, we feed the learned representations of drugs and targets to the multilayer perceptron model and predict the underlying interactions. Extensive results indicate that MIDTI significantly outperforms other baseline methods on the DTI prediction task. The results of the ablation experiments also confirm the effectiveness of the attention mechanism in the multi-view similarity network fusion strategy and the deep interactive attention mechanism.

AVAILABILITY AND IMPLEMENTATION

https://github.com/XuLew/MIDTI.

Design of a multi-category drug information integration platform for intelligent pharmacy management: A needs analysis study

A drug store was never just an area to fill personal solution. Patients considered drug specialists to be counsels, somebody who could help them pick an over-the-counter treatment or understanding the portion and directions for a solution. Drug stores, similar to the remainder of the medical services business, are going through changes. Nowadays, one of the main highlights of any structure is the board. The executives give the refinement needed to wrap up any responsibility in a particular way. The executive framework of a drug store can be utilized to deal with most drug store related errands. This report has provided data on the best way to fabricate and execute a Pharmacy Management System. The primary objective of this system is to expand exactness, just as security and proficiency, in the drug shop. This undertaking is focused on the drug store area, determined to offer engaging and reasonable programming answers to assist them with modernizing to rival shops (helping out other equal modules in a similar examination program). This study will clarify the system's thoughts concerning the board issues and arrangements of a drug store. Likewise, this study covers the main parts of the Pharmacy application's investigation, execution, and look.

NGCN: Drug-target interaction prediction by integrating information and feature learning from heterogeneous network

Drug-target interaction (DTI) prediction is essential for new drug design and development. Constructing heterogeneous network based on diverse information about drugs, proteins and diseases provides new opportunities for DTI prediction. However, the inherent complexity, high dimensionality and noise of such a network prevent us from taking full advantage of these network characteristics. This article proposes a novel method, NGCN, to predict drug-target interactions from an integrated heterogeneous network, from which to extract relevant biological properties and association information while maintaining the topology information. It focuses on learning the topology representation of drugs and targets to improve the performance of DTI prediction. Unlike traditional methods, it focuses on learning the low-dimensional topology representation of drugs and targets via graph-based convolutional neural network. NGCN achieves substantial performance improvements over other state-of-the-art methods, such as a nearly 1.0% increase in AUPR value. Moreover, we verify the robustness of NGCN through benchmark tests, and the experimental results demonstrate it is an extensible framework capable of combining heterogeneous information for DTI prediction.

SiSGC: A Drug Repositioning Prediction Model Based on Heterogeneous Simplifying Graph Convolution

Drug repositioning plays a key role in disease treatment. With the large-scale chemical data increasing, many computational methods are utilized for drug-disease association prediction. However, most of the existing models neglect the positive influence of non-Euclidean data and multisource information, and there is still a critical issue for graph neural networks regarding how to set the feature diffuse distance. To solve the problems, we proposed SiSGC, which makes full use of the biological knowledge information as initial features and learns the structure information from the constructed heterogeneous graph with the adaptive selection of the information diffuse distance. Then, the structural features are fused with the denoised similarity information and fed to the advanced classifier of CatBoost to make predictions. Three different data sets are used to confirm the robustness and generalization of SiSGC under two splitting strategies. Experiment results demonstrate that the proposed model achieves superior performance compared with the six leading methods and four variants. Our case study on breast neoplasms further indicates that SiSGC is trustworthy and robust yet simple. We also present four drugs for breast cancer treatment with high confidence and further give an explanation for demonstrating the rationality. There is no doubt that SiSGC can be used as a beneficial supplement for drug repositioning.

SMGCN: Multiple Similarity and Multiple Kernel Fusion Based Graph Convolutional Neural Network for Drug-Target Interactions Prediction

Accurately identifying potential drug-target interactions (DTIs) is a critical step in accelerating drug discovery. Despite many studies that have been conducted over the past decades, detecting DTIs remains a highly challenging and complicated process. Therefore, we propose a novel method called SMGCN, which combines multiple similarity and multiple kernel fusion based on Graph Convolutional Network (GCN) to predict DTIs. In order to capture the features of the network structure and fully explore direct or indirect relationships between nodes, we propose the method of multiple similarity, which combines similarity fusion matrices with Random Walk with Restart (RWR) and cosine similarity. Then, we use GCN to extract multi-layer low-dimensional embedding features. Unlike traditional GCN methods, we incorporate Multiple Kernel Learning (MKL). Finally, we use the Dual Laplace Regularized Least Squares method to predict novel DTIs through combinatorial kernels in drug and target spaces. We conduct experiments on a golden standard dataset, and demonstrate the effectiveness of our proposed model in predicting DTIs through showing significant improvements in Area Under the Curve (AUC) and Area Under the Precision-Recall Curve (AUPR). In addition, our model can also discover some new DTIs, which can be verified by the KEGG BRITE Database and relevant literature.

AttentionMGT-DTA: A multi-modal drug-target affinity prediction using graph transformer and attention mechanism

The accurate prediction of drug-target affinity (DTA) is a crucial step in drug discovery and design. Traditional experiments are very expensive and time-consuming. Recently, deep learning methods have achieved notable performance improvements in DTA prediction. However, one challenge for deep learning-based models is appropriate and accurate representations of drugs and targets, especially the lack of effective exploration of target representations. Another challenge is how to comprehensively capture the interaction information between different instances, which is also important for predicting DTA. In this study, we propose AttentionMGT-DTA, a multi-modal attention-based model for DTA prediction. AttentionMGT-DTA represents drugs and targets by a molecular graph and binding pocket graph, respectively. Two attention mechanisms are adopted to integrate and interact information between different protein modalities and drug-target pairs. The experimental results showed that our proposed model outperformed state-of-the-art baselines on two benchmark datasets. In addition, AttentionMGT-DTA also had high interpretability by modeling the interaction strength between drug atoms and protein residues. Our code is available at https://github.com/JK-Liu7/AttentionMGT-DTA.

MolCAP: Molecular Chemical reActivity Pretraining and prompted-finetuning enhanced molecular representation learning

Molecular representation learning (MRL) is a fundamental task for drug discovery. However, previous deep-learning (DL) methods focus excessively on learning robust inner-molecular representations by mask-dominated pretraining frameworks, neglecting abundant chemical reactivity molecular relationships that have been demonstrated as the determining factor for various molecular property prediction tasks. Here, we present MolCAP to promote MRL, a graph-pretraining Transformer based on chemical reactivity (IMR) knowledge with prompted finetuning. Results show that MolCAP outperforms comparative methods based on traditional molecular pretraining frameworks, in 13 publicly available molecular datasets across a diversity of biomedical tasks. Prompted by MolCAP, even basic graph neural networks are capable of achieving surprising performance that outperforms previous models, indicating the promising prospect of applying reactivity information to MRL. In addition, manually designed molecular templets are potential to uncover the dataset bias. All in all, we expect our MolCAP to gain more chemical meaningful insights for the entire process of drug discovery.

Identification of drug-side effect association via correntropy-loss based matrix factorization with neural tangent kernel

Adverse drug reactions include side effects, allergic reactions, and secondary infections. Severe adverse reactions can cause cancer, deformity, or mutation. The monitoring of drug side effects is an important support for post marketing safety supervision of drugs, and an important basis for revising drug instructions. Its purpose is to timely detect and control drug safety risks. Traditional methods are time-consuming. To accelerate the discovery of side effects, we propose a machine learning based method, called correntropy-loss based matrix factorization with neural tangent kernel (CLMF-NTK), to solve the prediction of drug side effects. Our method and other computational methods are tested on three benchmark datasets, and the results show that our method achieves the best predictive performance.

Graph regularized non-negative matrix factorization with [Formula: see text] norm regularization terms for drug-target interactions prediction

BACKGROUND

Identifying drug-target interactions (DTIs) plays a key role in drug development. Traditional wet experiments to identify DTIs are costly and time consuming. Effective computational methods to predict DTIs are useful to speed up the process of drug discovery. A variety of non-negativity matrix factorization based methods are proposed to predict DTIs, but most of them overlooked the sparsity of feature matrices and the convergence of adopted matrix factorization algorithms, therefore their performances can be further improved.

RESULTS

In order to predict DTIs more accurately, we propose a novel method iPALM-DLMF. iPALM-DLMF models DTIs prediction as a problem of non-negative matrix factorization with graph dual regularization terms and [Formula: see text] norm regularization terms. The graph dual regularization terms are used to integrate the information from the drug similarity matrix and the target similarity matrix, and [Formula: see text] norm regularization terms are used to ensure the sparsity of the feature matrices obtained by non-negative matrix factorization. To solve the model, iPALM-DLMF adopts non-negative double singular value decomposition to initialize the nonnegative matrix factorization, and an inertial Proximal Alternating Linearized Minimization iterating process, which has been proved to converge to a KKT point, to obtain the final result of the matrix factorization. Extensive experimental results show that iPALM-DLMF has better performance than other state-of-the-art methods. In case studies, in 50 highest-scoring proteins targeted by the drug gabapentin predicted by iPALM-DLMF, 46 have been validated, and in 50 highest-scoring drugs targeting prostaglandin-endoperoxide synthase 2 predicted by iPALM-DLMF, 47 have been validated.

Adaptive channel-modulated personalized federated learning for magnetic resonance image reconstruction

Magnetic resonance imaging (MRI) is extensively utilized in clinical practice for diagnostic purposes, owing to its non-invasive nature and remarkable ability to provide detailed characterization of soft tissues. However, its drawback lies in the prolonged scanning time. To accelerate MR imaging, how to reconstruct MR images from under-sampled data quickly and accurately has drawn intensive research interest; it, however, remains a challenging task. While some deep learning models have achieved promising performance in MRI reconstruction, these models usually require a substantial quantity of paired data for training, which proves challenging to gather and share owing to high scanning costs and data privacy concerns. Federated learning (FL) is a potential tool to alleviate these difficulties. It enables multiple clinical clients to collaboratively train a global model without compromising privacy. However, it is extremely challenging to fit a single model to diverse data distributions of different clients. Moreover, existing FL algorithms treat the features of each channel equally, lacking discriminative learning ability across feature channels, and hence hindering their representational capability. In this study, we propose a novel Adaptive Channel-Modulated Federal learning framework for personalized MRI reconstruction, dubbed as ACM-FedMRI. Specifically, considering each local client may focus on features in different channels, we first design a client-specific hypernetwork to guide the channel selection operation in order to optimize the extracted features. Additionally, we introduce a performance-based channel decoupling scheme, which dynamically separates the global model at the channel level to facilitate personalized adjustments based on the performance of individual clients. This approach eliminates the need for heuristic design of specific personalization layers. Extensive experiments on four datasets under two different settings show that our ACM-FedMRI achieves outstanding results compared to other cutting-edge federated learning techniques in the field of MRI reconstruction.

Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery

Artificial intelligence (AI) has permeated various sectors, including the pharmaceutical industry and research, where it has been utilized to efficiently identify new chemical entities with desirable properties. The application of AI algorithms to drug discovery presents both remarkable opportunities and challenges. This review article focuses on the transformative role of AI in medicinal chemistry. We delve into the applications of machine learning and deep learning techniques in drug screening and design, discussing their potential to expedite the early drug discovery process. In particular, we provide a comprehensive overview of the use of AI algorithms in predicting protein structures, drug-target interactions, and molecular properties such as drug toxicity. While AI has accelerated the drug discovery process, data quality issues and technological constraints remain challenges. Nonetheless, new relationships and methods have been unveiled, demonstrating AI's expanding potential in predicting and understanding drug interactions and properties. For its full potential to be realized, interdisciplinary collaboration is essential. This review underscores AI's growing influence on the future trajectory of medicinal chemistry and stresses the importance of ongoing synergies between computational and domain experts.

Identification of SH2 domain-containing proteins and motifs prediction by a deep learning method

The Src Homology 2 (SH2) domain plays an important role in the signal transmission mechanism in organisms. It mediates the protein-protein interactions based on the combination between phosphotyrosine and motifs in SH2 domain. In this study, we designed a method to identify SH2 domain-containing proteins and non-SH2 domain-containing proteins through deep learning technology. Firstly, we collected SH2 and non-SH2 domain-containing protein sequences including multiple species. We built six deep learning models through DeepBIO after data preprocessing and compared their performance. Secondly, we selected the model with the strongest comprehensive ability to conduct training and test separately again, and analyze the results visually. It was found that 288-dimensional (288D) feature could effectively identify two types of proteins. Finally, motifs analysis discovered the specific motif YKIR and revealed its function in signal transduction. In summary, we successfully identified SH2 domain and non-SH2 domain proteins through deep learning method, and obtained 288D features that perform best. In addition, we found a new motif YKIR in SH2 domain, and analyzed its function which helps to further understand the signaling mechanisms within the organism.

Prediction of drug-target interactions via neural tangent kernel extraction feature matrix factorization model

Drug discovery is a complex and lengthy process that often requires years of research and development. Therefore, drug research and development require a lot of investment and resource support, as well as professional knowledge, technology, skills, and other elements. Predicting of drug-target interactions (DTIs) is an important part of drug development. If machine learning is used to predict DTIs, the cost and time of drug development can be significantly reduced. Currently, machine learning methods are widely used to predict DTIs. In this study neighborhood regularized logistic matrix factorization method based on extracted features from a neural tangent kernel (NTK) to predict DTIs. First, the potential feature matrix of drugs and targets is extracted from the NTK model, then the corresponding Laplacian matrix is constructed according to the feature matrix. Next, the Laplacian matrix of the drugs and targets is used as the condition for matrix factorization to obtain two low-dimensional matrices. Finally, the matrix of the predicted DTIs was obtained by multiplying these two low-dimensional matrices. For the four gold standard datasets, the present method is significantly better than the other methods that is compared to, indicating that the automatic feature extraction method using the deep learning model is competitive compared with the manual feature selection method.

Mutual-DTI: A mutual interaction feature-based neural network for drug-target protein interaction prediction

The prediction of drug-target protein interaction (DTI) is a crucial task in the development of new drugs in modern medicine. Accurately identifying DTI through computer simulations can significantly reduce development time and costs. In recent years, many sequence-based DTI prediction methods have been proposed, and introducing attention mechanisms has improved their forecasting performance. However, these methods have some shortcomings. For example, inappropriate dataset partitioning during data preprocessing can lead to overly optimistic prediction results. Additionally, only single non-covalent intermolecular interactions are considered in the DTI simulation, ignoring the complex interactions between their internal atoms and amino acids. In this paper, we propose a network model called Mutual-DTI that predicts DTI based on the interaction properties of sequences and a Transformer model. We use multi-head attention to extract the long-distance interdependent features of the sequence and introduce a module to extract the sequence's mutual interaction features in mining complex reaction processes of atoms and amino acids. We evaluate the experiments on two benchmark datasets, and the results show that Mutual-DTI outperforms the latest baseline significantly. In addition, we conduct ablation experiments on a label-inversion dataset that is split more rigorously. The results show that there is a significant improvement in the evaluation metrics after introducing the extracted sequence interaction feature module. This suggests that Mutual-DTI may contribute to modern medical drug development research. The experimental results show the effectiveness of our approach. The code for Mutual-DTI can be downloaded from https://github.com/a610lab/Mutual-DTI.

Identification of DNA-binding proteins by Kernel Sparse Representation via L2,1-matrix norm

An understanding of DNA-binding proteins is helpful in exploring the role that proteins play in cell biology. Furthermore, the prediction of DNA-binding proteins is essential for the chemical modification and structural composition of DNA, and is of great importance in protein functional analysis and drug design. In recent years, DNA-binding protein prediction has typically used machine learning-based methods. The prediction accuracy of various classifiers has improved considerably, but researchers continue to spend time and effort on improving prediction performance. In this paper, we combine protein sequence evolutionary information with a classification method based on kernel sparse representation for the prediction of DNA-binding proteins, and based on the field of machine learning, a model for the identification of DNA-binding proteins by sequence information was finally proposed. Based on the confirmation of the final experimental results, we achieved good prediction accuracy on both the PDB1075 and PDB186 datasets. Our training result for cross-validation on PDB1075 was 81.37%, and our independent test result on PDB186 was 83.9%, both of which outperformed the other methods to some extent. Therefore, the proposed method in this paper is proven to be effective and feasible for predicting DNA-binding proteins.

Predicting microbe-drug associations with structure-enhanced contrastive learning and self-paced negative sampling strategy

MOTIVATION

Predicting the associations between human microbes and drugs (MDAs) is one critical step in drug development and precision medicine areas. Since discovering these associations through wet experiments is time-consuming and labor-intensive, computational methods have already been an effective way to tackle this problem. Recently, graph contrastive learning (GCL) approaches have shown great advantages in learning the embeddings of nodes from heterogeneous biological graphs (HBGs). However, most GCL-based approaches don't fully capture the rich structure information in HBGs. Besides, fewer MDA prediction methods could screen out the most informative negative samples for effectively training the classifier. Therefore, it still needs to improve the accuracy of MDA predictions.

RESULTS

In this study, we propose a novel approach that employs the Structure-enhanced Contrastive learning and Self-paced negative sampling strategy for Microbe-Drug Association predictions (SCSMDA). Firstly, SCSMDA constructs the similarity networks of microbes and drugs, as well as their different meta-path-induced networks. Then SCSMDA employs the representations of microbes and drugs learned from meta-path-induced networks to enhance their embeddings learned from the similarity networks by the contrastive learning strategy. After that, we adopt the self-paced negative sampling strategy to select the most informative negative samples to train the MLP classifier. Lastly, SCSMDA predicts the potential microbe-drug associations with the trained MLP classifier. The embeddings of microbes and drugs learning from the similarity networks are enhanced with the contrastive learning strategy, which could obtain their discriminative representations. Extensive results on three public datasets indicate that SCSMDA significantly outperforms other baseline methods on the MDA prediction task. Case studies for two common drugs could further demonstrate the effectiveness of SCSMDA in finding novel MDA associations.

AVAILABILITY

The source code is publicly available on GitHub https://github.com/Yue-Yuu/SCSMDA-master.

MecDDI: Clarified Drug-Drug Interaction Mechanism Facilitating Rational Drug Use and Potential Drug-Drug Interaction Prediction

Drug-drug interactions (DDIs) are a major concern in clinical practice and have been recognized as one of the key threats to public health. To address such a critical threat, many studies have been conducted to clarify the mechanism underlying each DDI, based on which alternative therapeutic strategies are successfully proposed. Moreover, artificial intelligence-based models for predicting DDIs, especially multilabel classification models, are highly dependent on a reliable DDI data set with clear mechanistic information. These successes highlight the imminent necessity to have a platform providing mechanistic clarifications for a large number of existing DDIs. However, no such platform is available yet. In this study, a platform entitled "MecDDI" was therefore introduced to systematically clarify the mechanisms underlying the existing DDIs. This platform is unique in (a) clarifying the mechanisms underlying over 1,78,000 DDIs by explicit descriptions and graphic illustrations and (b) providing a systematic classification for all collected DDIs based on the clarified mechanisms. Due to the long-lasting threats of DDIs to public health, MecDDI could offer medical scientists a clear clarification of DDI mechanisms, support healthcare professionals to identify alternative therapeutics, and prepare data for algorithm scientists to predict new DDIs. MecDDI is now expected as an indispensable complement to the available pharmaceutical platforms and is freely accessible at: https://idrblab.org/mecddi/.

A review of methods for predicting DNA N6-methyladenine sites

Deoxyribonucleic acid(DNA) N6-methyladenine plays a vital role in various biological processes, and the accurate identification of its site can provide a more comprehensive understanding of its biological effects. There are several methods for 6mA site prediction. With the continuous development of technology, traditional techniques with the high costs and low efficiencies are gradually being replaced by computer methods. Computer methods that are widely used can be divided into two categories: traditional machine learning and deep learning methods. We first list some existing experimental methods for predicting the 6mA site, then analyze the general process from sequence input to results in computer methods and review existing model architectures. Finally, the results were summarized and compared to facilitate subsequent researchers in choosing the most suitable method for their work.

MNNMDA: Predicting human microbe-disease association via a method to minimize matrix nuclear norm

Identifying the potential associations between microbes and diseases is the first step for revealing the pathological mechanisms of microbe-associated diseases. However, traditional culture-based microbial experiments are expensive and time-consuming. Thus, it is critical to prioritize disease-associated microbes by computational methods for further experimental validation. In this study, we proposed a novel method called MNNMDA, to predict microbe-disease associations (MDAs) by applying a Matrix Nuclear Norm method into known microbe and disease data. Specifically, we first calculated Gaussian interaction profile kernel similarity and functional similarity for diseases and microbes. Then we constructed a heterogeneous information network by combining the integrated disease similarity network, the integrated microbe similarity network and the known microbe-disease bipartite network. Finally, we formulated the microbe-disease association prediction problem as a low-rank matrix completion problem, which was solved by minimizing the nuclear norm of a matrix with a few regularization terms. We tested the performances of MNNMDA in three datasets including HMDAD, Disbiome, and Combined Data with small, medium and large sizes respectively. We also compared MNNMDA with 5 state-of-the-art methods including KATZHMDA, LRLSHMDA, NTSHMDA, GATMDA, and KGNMDA, respectively. MNNMDA achieved area under the ROC curves (AUROC) of 0.9536 and 0.9364 respectively on HDMAD and Disbiome, better than the AUCs of compared methods under the 5-fold cross-validation for all microbe-disease associations. It also obtained a relatively good performance with AUROC 0.8858 in the combined data. In addition, MNNMDA was also better than other methods in area under precision and recall curve (AUPR) under the 5-fold cross-validation for all associations, and in both AUROC and AUPR under the 5-fold cross-validation for diseases and the 5-fold cross-validation for microbes. Finally, the case studies on colon cancer and inflammatory bowel disease (IBD) also validated the effectiveness of MNNMDA. In conclusion, MNNMDA is an effective method in predicting microbe-disease associations.

Availability

The codes and data for this paper are freely available at Github https://github.com/Haiyan-Liu666/MNNMDA.

Utilize a few features to classify presynaptic and postsynaptic neurotoxins

Neurotoxins are a class of proteins that have a significant damaging effect on nerve tissue. Neurotoxins are classified into presynaptic neurotoxins and postsynaptic neurotoxins, and accurate identification of neurotoxins plays a key role in drug development. In this study, 90 presynaptic neurotoxins and 165 postsynaptic neurotoxins were classified. The features of the presynaptic and postsynaptic neurotoxin sequences were extracted using the AutoProp feature extraction method and feature selection was performed using the maximum relevance maximum distance (MRMD) program, Finally, only two features were retained to achieve 84.7% classification accuracy. Moreover, it was found that the two retained features were present in the conserved sites and motifs of presynaptic neurotoxins and could represent the critical structures of presynaptic neurotoxins. This method demonstrates that using a few key features to classify proteins can effectively identify critical protein structures.

Drug-target binding affinity prediction method based on a deep graph neural network

The development of new drugs is a long and costly process, Computer-aided drug design reduces development costs while computationally shortening the new drug development cycle, in which DTA (Drug-Target binding Affinity) prediction is a key step to screen out potential drugs. With the development of deep learning, various types of deep learning models have achieved notable performance in a wide range of fields. Most current related studies focus on extracting the sequence features of molecules while ignoring the valuable structural information; they employ sequence data that represent only the elemental composition of molecules without considering the molecular structure maps that contain structural information. In this paper, we use graph neural networks to predict DTA based on corresponding graph data of drugs and proteins, and we achieve competitive performance on two benchmark datasets, Davis and KIBA. In particular, an MSE of 0.227 and CI of 0.895 were obtained on Davis, and an MSE of 0.127 and CI of 0.903 were obtained on KIBA.

iSnoDi-LSGT: identifying snoRNA-disease associations based on local similarity constraints and global topological constraints

Growing evidence proves that small nucleolar RNAs (snoRNAs) have important functions in various biological processes, the malfunction of which leads to the emergence and development of complex diseases. However, identifying snoRNA-disease associations is an ongoing challenging task due to the considerable time- and money-consuming biological experiments. Therefore, it is urgent to design efficient and economical methods for the identification of snoRNA-disease associations. In this regard, we propose a computational method named iSnoDi-LSGT, which utilizes snoRNA sequence similarity and disease similarity as local similarity constraints. The iSnoDi-LSGT predictor further employs network embedding technology to extract topological features of snoRNAs and diseases, based on which snoRNA topological similarity and disease topological similarity are calculated as global topological constraints. To the best of our knowledge, the iSnoDi-LSGT is the first computational method for snoRNA-disease association identification. The experimental results indicate that the iSnoDi-LSGT predictor can effectively predict unknown snoRNA-disease associations. The web server of the iSnoDi-LSGT predictor is freely available at http://bliulab.net/iSnoDi-LSGT.

Identification of drug-side effect association via restricted Boltzmann machines with penalized term

In the entire life cycle of drug development, the side effect is one of the major failure factors. Severe side effects of drugs that go undetected until the post-marketing stage leads to around two million patient morbidities every year in the United States. Therefore, there is an urgent need for a method to predict side effects of approved drugs and new drugs. Following this need, we present a new predictor for finding side effects of drugs. Firstly, multiple similarity matrices are constructed based on the association profile feature and drug chemical structure information. Secondly, these similarity matrices are integrated by Centered Kernel Alignment-based Multiple Kernel Learning algorithm. Then, Weighted K nearest known neighbors is utilized to complement the adjacency matrix. Next, we construct Restricted Boltzmann machines (RBM) in drug space and side effect space, respectively, and apply a penalized maximum likelihood approach to train model. At last, the average decision rule was adopted to integrate predictions from RBMs. Comparison results and case studies demonstrate, with four benchmark datasets, that our method can give a more accurate and reliable prediction result.

MHADTI: predicting drug-target interactions via multiview heterogeneous information network embedding with hierarchical attention mechanisms

MOTIVATION

Discovering the drug-target interactions (DTIs) is a crucial step in drug development such as the identification of drug side effects and drug repositioning. Since identifying DTIs by web-biological experiments is time-consuming and costly, many computational-based approaches have been proposed and have become an efficient manner to infer the potential interactions. Although extensive effort is invested to solve this task, the prediction accuracy still needs to be improved. More especially, heterogeneous network-based approaches do not fully consider the complex structure and rich semantic information in these heterogeneous networks. Therefore, it is still a challenge to predict DTIs efficiently.

RESULTS

In this study, we develop a novel method via Multiview heterogeneous information network embedding with Hierarchical Attention mechanisms to discover potential Drug-Target Interactions (MHADTI). Firstly, MHADTI constructs different similarity networks for drugs and targets by utilizing their multisource information. Combined with the known DTI network, three drug-target heterogeneous information networks (HINs) with different views are established. Secondly, MHADTI learns embeddings of drugs and targets from multiview HINs with hierarchical attention mechanisms, which include the node-level, semantic-level and graph-level attentions. Lastly, MHADTI employs the multilayer perceptron to predict DTIs with the learned deep feature representations. The hierarchical attention mechanisms could fully consider the importance of nodes, meta-paths and graphs in learning the feature representations of drugs and targets, which makes their embeddings more comprehensively. Extensive experimental results demonstrate that MHADTI performs better than other SOTA prediction models. Moreover, analysis of prediction results for some interested drugs and targets further indicates that MHADTI has advantages in discovering DTIs.

AVAILABILITY AND IMPLEMENTATION

https://github.com/pxystudy/MHADTI.

DRESIS: the first comprehensive landscape of drug resistance information

Widespread drug resistance has become the key issue in global healthcare. Extensive efforts have been made to reveal not only diverse diseases experiencing drug resistance, but also the six distinct types of molecular mechanisms underlying this resistance. A database that describes a comprehensive list of diseases with drug resistance (not just cancers/infections) and all types of resistance mechanisms is now urgently needed. However, no such database has been available to date. In this study, a comprehensive database describing drug resistance information named 'DRESIS' was therefore developed. It was introduced to (i) systematically provide, for the first time, all existing types of molecular mechanisms underlying drug resistance, (ii) extensively cover the widest range of diseases among all existing databases and (iii) explicitly describe the clinically/experimentally verified resistance data for the largest number of drugs. Since drug resistance has become an ever-increasing clinical issue, DRESIS is expected to have great implications for future new drug discovery and clinical treatment optimization. It is now publicly accessible without any login requirement at: https://idrblab.org/dresis/.

DeepPSE: Prediction of polypharmacy side effects by fusing deep representation of drug pairs and attention mechanism

Polypharmacy (multiple use of drugs) is an effective strategy for combating complex or co-existing diseases. However, a major consequence of polypharmacy is a higher risk of adverse side effects due to drug-drug interactions, which are rare and observed in relatively small clinical testing. Thus, identification of polypharmacy side effects remains challenging. Here, we propose a deep learning-based method, DeepPSE, to predict polypharmacy side effects in an end-to-end way. DeepPSE is composed of two main modules. First, multiple types of neural networks are constructed and fused to learn the deep representation of a drug pair. Second, the encoder block of transformer that includes self-attention mechanism is built to get latent features, which are further fed into the fully connected layer to predict polypharmacy side effects of drug pairs. Further, DeepPSE is compared with five baseline or state-of-the-art methods on a benchmark dataset of 964 types of polypharmacy side effects across 63473 drug pairs. Experimental results demonstrate that DeepPSE achieves better performance than that of all five methods. The source codes and data are available at https://github.com/ShenggengLin/DeepPSE.

Identification of Vesicle Transport Proteins via Hypergraph Regularized K-Local Hyperplane Distance Nearest Neighbour Model

The prediction of protein function is a common topic in the field of bioinformatics. In recent years, advances in machine learning have inspired a growing number of algorithms for predicting protein function. A large number of parameters and fairly complex neural networks are often used to improve the prediction performance, an approach that is time-consuming and costly. In this study, we leveraged traditional features and machine learning classifiers to boost the performance of vesicle transport protein identification and make the prediction process faster. We adopt the pseudo position-specific scoring matrix (PsePSSM) feature and our proposed new classifier hypergraph regularized k-local hyperplane distance nearest neighbour (HG-HKNN) to classify vesicular transport proteins. We address dataset imbalances with random undersampling. The results show that our strategy has an area under the receiver operating characteristic curve (AUC) of 0.870 and a Matthews correlation coefficient (MCC) of 0.53 on the benchmark dataset, outperforming all state-of-the-art methods on the same dataset, and other metrics of our model are also comparable to existing methods.

DNA-binding protein prediction based on deep transfer learning

The study of DNA binding proteins (DBPs) is of great importance in the biomedical field and plays a key role in this field. At present, many researchers are working on the prediction and detection of DBPs. Traditional DBP prediction mainly uses machine learning methods. Although these methods can obtain relatively high pre-diction accuracy, they consume large quantities of human effort and material resources. Transfer learning has certain advantages in dealing with such prediction problems. Therefore, in the present study, two features were extracted from a protein sequence, a transfer learning method was used, and two classical transfer learning algorithms were compared to transfer samples and construct data sets. In the final step, DBPs are detected by building a deep learning neural network model in a way that uses attention mechanisms.

Predicting miRNA-disease associations via learning multimodal networks and fusing mixed neighborhood information

MOTIVATION

In recent years, a large number of biological experiments have strongly shown that miRNAs play an important role in understanding disease pathogenesis. The discovery of miRNA-disease associations is beneficial for disease diagnosis and treatment. Since inferring these associations through biological experiments is time-consuming and expensive, researchers have sought to identify the associations utilizing computational approaches. Graph Convolutional Networks (GCNs), which exhibit excellent performance in link prediction problems, have been successfully used in miRNA-disease association prediction. However, GCNs only consider 1st-order neighborhood information at one layer but fail to capture information from high-order neighbors to learn miRNA and disease representations through information propagation. Therefore, how to aggregate information from high-order neighborhood effectively in an explicit way is still challenging.

RESULTS

To address such a challenge, we propose a novel method called mixed neighborhood information for miRNA-disease association (MINIMDA), which could fuse mixed high-order neighborhood information of miRNAs and diseases in multimodal networks. First, MINIMDA constructs the integrated miRNA similarity network and integrated disease similarity network respectively with their multisource information. Then, the embedding representations of miRNAs and diseases are obtained by fusing mixed high-order neighborhood information from multimodal network which are the integrated miRNA similarity network, integrated disease similarity network and the miRNA-disease association networks. Finally, we concentrate the multimodal embedding representations of miRNAs and diseases and feed them into the multilayer perceptron (MLP) to predict their underlying associations. Extensive experimental results show that MINIMDA is superior to other state-of-the-art methods overall. Moreover, the outstanding performance on case studies for esophageal cancer, colon tumor and lung cancer further demonstrates the effectiveness of MINIMDA.

AVAILABILITY AND IMPLEMENTATION

https://github.com/chengxu123/MINIMDA and http://120.79.173.96/.